On September 25, 2015, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Tresiba (insulin degludec injection) to improve blood sugar control in adults with diabetes.
What is Tresiba?
Tresiba is long-acting (basal) insulin approved for people with type 1 or type 2 diabetes and is injected under the skin once daily. It was rejected for approval in 2013 due to concerns that Tresiba harmed heart health, but those fears have since been quelled.
This approval may quicken the approval process for Xultophy, a blend of GLP-1 agonist Victoza and Tresiba specifically made for people with type 2 diabetes that may be more effective than Lantus.
• In studies of people with type 1 or type 2 diabetes, researchers found that Tresiba provided reduction in A1c
• It can be used with mealtime (bolus) insulin and with common oral diabetes drugs
• You can inject it at any time of the day, although injecting it at the same time every day is encouraged
• Provides a long duration of action, lasting beyond 42 hours
• Has eight weeks of shelf life at room temperature
• Available in the FlexTouch insulin pen, which is offered in two concentrations (80 and 160 units)
• Not to be used if you have increased ketones in your blood or urine, known as diabetic ketoacidosis
• May cause low blood sugar, which can be life-threatening
• People may have a severe allergic reaction to any insulin, including Tresiba, which can result in anaphylaxis
• Other common side effects include injection site reactions, itching, rash, edema, weight gain, and pitting at the injection site (called lipodystrophy)
"Since 1923, Novo Nordisk has been committed to advancing insulin therapy for patients with diabetes, and we are proud to bring forward the first new basal insulin molecule to be approved by the FDA in 10 years," said Jesper Høiland, president of Novo Nordisk in the United States and executive vice president of Novo Nordisk A/S. "Novo Nordisk is excited to launch Tresiba in the United States in the first quarter of 2016."
Are you interested in trying Tresiba, or have you already tried it? Let us know your thoughts in the comments below.
Image Source: Diabetes Daily